Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 2/20 | 0.41 |
| ▸ | FNTB | P49356 | 2/20 | 0.41 |
| ▸ | MME | P08473 | 5/20 | 0.41 |
| ▸ | CPA3 | P15088 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | THPO | P40225 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8682774 | 1.00 | NPSR1 (0.44) | NPSR1FNTAFNTBMMECPA3 | |
| SCHEMBL232516 | 1.00 | NPSR1 (0.44) | NPSR1FNTAFNTBMMECPA3 | |
| SCHEMBL4970029 | 0.87 | KIF11 (0.49) | ALOX15RECQL | |
| SCHEMBL29478394 | 0.86 | NPSR1 (0.42) | NPSR1MMECPA3FOLH1 | |
| SCHEMBL28500174 | 0.86 | NPSR1 (0.42) | NPSR1MMECPA3FOLH1 | |
| SCHEMBL993651 | 0.84 | NPSR1 (0.45) | NPSR1FNTAFNTBMME | |
| SCHEMBL2604614 | 0.84 | NPSR1 (0.45) | NPSR1FNTAFNTBMME | |
| SCHEMBL1899106 | 0.84 | NPSR1 (0.45) | NPSR1FNTAFNTBMME | |
| SCHEMBL10795600 | 0.83 | MDM4 (0.43) | THRB | |
| SCHEMBL10889787 | 0.83 | NPSR1 (0.42) | NPSR1FNTAFNTBMMEKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2047 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| EP-4590346-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP) INHIBITORS, FAP CONJUGATES, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | Nuclidium AG (CH) | 2025-07-30 | — | — | EP | claimed |
| EP-4086250-B1 | MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND MTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2024-12-11 | — | — | EP | claimed |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-10-17 | — | — | US | claimed |
| WO-2024064968-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP) INHIBITORS, FAP CONJUGATES, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | NUCLIDIUM AG (CH) | 2024-03-28 | — | — | WO | claimed |
| EP-2805945-B1 | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors | MSD ITALIA SRL (IT) | 2019-04-03 | — | — | EP | claimed |
| US-20170360950-A1 | DRUG DELIVERY CONJUGATES CONTAINING UNNATURAL AMINO ACIDS AND METHODS FOR USING | ENDOCYTE INC (US) | 2017-12-21 | — | — | US | claimed |
| US-9707248-B2 | Use of thiopyrimidinecarboxamide for treating cancer | SYNTRIX BIOSYSTEMS INC. (US) | 2017-07-18 | — | — | US | claimed |
| US-20170014435-A1 | USE OF THIOPYRIMIDINECARBOXAMIDE FOR TREATING CANCER | SYNTRIX BIOSYSTEMS INC (US) | 2017-01-19 | — | — | US | claimed |
| US-20040132736-A1 | 17 Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION | 2004-07-08 | — | — | US | claimed |
| EP-1423381-A1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | Schering Corporation (US) | 2004-06-02 | — | — | EP | claimed |
| WO-2004030627-A2 | SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-15 | — | — | WO | claimed |
| US-20040072760-A1 | Synergistic methods and compositions for treating cancer | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-15 | — | — | US | claimed |
| US-20030232837-A1 | 17-Beta hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION | 2003-12-18 | — | — | US | claimed |
| EP-1313725-A1 | TRICYCLIC ANTITUMOR COMPOUNDS BEING FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2003-05-28 | — | — | EP | claimed |
| WO-2003033487-A1 | PIPERIDINE- AND PIPERAZINEACETAMINES AS 17BETA HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | SCHERING CORPORATION (US) | 2003-04-24 | — | — | WO | claimed |
| WO-2003022835-A1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | SCHERING CORPORATION (US) | 2003-03-20 | — | — | WO | claimed |
| US-20020198216-A1 | Novel farnesyl protein transferase inhibitors as antitumor agents | PHARMACOPEIA DRUG DISCOVERY | 2002-12-26 | — | — | US | claimed |
| WO-2002018368-A1 | TRICYCLIC ANTITUMOR COMPOUNDS BEING FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2002-03-07 | — | — | WO | claimed |